This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Xenetic Biosciences 관리

관리 기준 확인 3/4

We currently do not have sufficient information about the CEO.

주요 정보

Jeff Eisenberg

최고 경영자

US$632.8k

총 보상

CEO 급여 비율	63.9%
CEO 임기	5.8yrs
CEO 소유권	n/a
경영진 평균 재임 기간	6.3yrs
이사회 평균 재임 기간	4.4yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Jeff Eisenberg 의 보수는 Xenetic Biosciences 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2023	n/a	n/a	-US$6m
Dec 31 2022	US$633k	US$404k	-US$7m
Sep 30 2022	n/a	n/a	-US$7m
Jun 30 2022	n/a	n/a	-US$7m
Mar 31 2022	n/a	n/a	-US$6m
Dec 31 2021	US$750k	US$368k	-US$6m
Sep 30 2021	n/a	n/a	-US$5m
Jun 30 2021	n/a	n/a	-US$11m
Mar 31 2021	n/a	n/a	-US$11m
Dec 31 2020	US$446k	US$350k	-US$11m
Sep 30 2020	n/a	n/a	-US$11m
Jun 30 2020	n/a	n/a	-US$14m
Mar 31 2020	n/a	n/a	-US$14m
Dec 31 2019	US$603k	US$300k	-US$18m
Sep 30 2019	n/a	n/a	-US$19m
Jun 30 2019	n/a	n/a	-US$10m
Mar 31 2019	n/a	n/a	-US$11m
Dec 31 2018	US$318k	US$300k	-US$7m
Sep 30 2018	n/a	n/a	-US$1m
Jun 30 2018	n/a	n/a	-US$2m
Mar 31 2018	n/a	n/a	-US$3m
Dec 31 2017	US$815k	US$300k	-US$4m
Sep 30 2017	n/a	n/a	-US$12m
Jun 30 2017	n/a	n/a	-US$13m
Mar 31 2017	n/a	n/a	-US$58m
Dec 31 2016	US$694k	US$25k	-US$58m

보상 대 시장: Jeff's total compensation ($USD632.83K) is above average for companies of similar size in the German market ($USD418.12K).

보상과 수익: Jeff's compensation has been consistent with company performance over the past year.

CEO

Jeff Eisenberg (57 yo)

5.8yrs

테뉴어

US$632,827

보상

Mr. Jeffrey F. Eisenberg, also known as Jeff, Esq., has been the Chief Executive Officer of Xenetic Biosciences, Inc. since October 26, 2017; has been its Director since July 11, 2016 and also serves as it...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jeffrey Eisenberg	CEO, President & Director	5.8yrs	US$632.83k	데이터 없음
James Parslow	CFO, COO & Corporate Secretary	6.3yrs	US$473.99k	0% € 0
Curtis Lockshin	Chief Scientific Officer	6.6yrs	US$470.37k	0% € 0

6.3yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 관리: 3XB0's management team is seasoned and experienced (6.3 years average tenure).

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jeffrey Eisenberg	CEO, President & Director	7.1yrs	US$632.83k	데이터 없음
Adam Logal	Independent Chairman of the Board	6yrs	US$59.56k	0% € 0
Roger Kornberg	Independent Director	7.5yrs	US$59.56k	0% € 0
Firdaus Dastoor	Independent Director	9.6yrs	US$59.56k	0% € 0
James Callaway	Independent Director	6yrs	US$59.56k	0% € 0
Guenther Koehne	Member of Scientific Advisory Board	4.3yrs	데이터 없음	데이터 없음
Matthew Frigault	Member of Scientific Advisory Board	4.6yrs	데이터 없음	데이터 없음
Alexey Vinogradov	Independent Director	4.1yrs	US$59.56k	1.23% € 61.4k
Grigory Borisenko	Independent Non-Executive Director	3.9yrs	US$59.56k	데이터 없음
Maksim Mamonkin	Member of Scientific Advisory Board	3.5yrs	데이터 없음	데이터 없음
Allan Tsung	Member of Scientific Advisory Board	1.3yrs	데이터 없음	데이터 없음
Jonathan Spicer	Member of Scientific Advisory Board	less than a year	데이터 없음	데이터 없음

4.4yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 이사회: 3XB0's board of directors are considered experienced (4.4 years average tenure).

This company listing is no longer active

Xenetic Biosciences 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Xenetic Biosciences, Inc. Announces the Appointment of James Parslow as Interim Chief Executive Officer

Xenetic Biosciences, Inc., Annual General Meeting, Dec 06, 2023

Xenetic Biosciences, Inc., Annual General Meeting, Dec 21, 2022

Xenetic Biosciences, Inc. Announces the Appointment of Jonathan Spicer to its Scientific Advisory Board

Xenetic Biosciences, Inc., Annual General Meeting, Dec 07, 2022

Xenetic Biosciences, Inc. Appoints Allan Tsung, to Its Scientific Advisory Board

Recent updates

Xenetic Biosciences, Inc. Announces the Appointment of James Parslow as Interim Chief Executive Officer

CLS Therapeutics Discloses its Views on Xenetic Biosciences

Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of Its DNase-Based Oncology Platform

Xenetic Biosciences, Inc., Annual General Meeting, Dec 06, 2023

First quarter 2023 earnings released: US$0.056 loss per share (vs US$0.12 loss in 1Q 2022)

Full year 2022 earnings released: US$0.46 loss per share (vs US$0.55 loss in FY 2021)

Xenetic Biosciences, Inc., Annual General Meeting, Dec 21, 2022

Xenetic Biosciences Receives a Non-Compliance Letter from Nasdaq

Xenetic Biosciences, Inc. Announces the Appointment of Jonathan Spicer to its Scientific Advisory Board

Third quarter 2022 earnings released: US$0.056 loss per share (vs US$0.13 loss in 3Q 2021)

Xenetic Biosciences, Inc., Annual General Meeting, Dec 07, 2022

Xenetic Biosciences, Inc. announced that it expects to receive $0.488835 million in funding from CLS Therapeutics, Inc.

Xenetic Biosciences, Inc. Appoints Allan Tsung, to Its Scientific Advisory Board

Second quarter 2022 earnings released: US$0.19 loss per share (vs US$0.13 loss in 2Q 2021)

Xenetic Biosciences Receives Written Notification from the Listing Qualifications Department of the Nasdaq

First quarter 2022 earnings released: US$0.12 loss per share (vs US$0.15 loss in 1Q 2021)

Xenetic Biosciences, Inc. announced that it has received $0.86625 million in funding

High number of new directors

Third quarter 2021 earnings released: US$0.13 loss per share (vs US$1.20 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.15 loss in 2Q 2020)

High number of new and inexperienced directors

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령